RMC-9805 for Solid Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new oral drug, RMC-9805, in adults with a specific type of cancer mutation (KRAS G12D). The drug aims to block a faulty gene to potentially stop cancer growth.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Revolution Medicines, Inc.
Principal Investigator
Revolution Medicines, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have a specific mutation called KRAS G12D. Participants must have tried standard treatments without success or could not tolerate them, and should be in fairly good health (ECOG status 0 or 1) with their organs working well. People can't join if they have issues absorbing pills, brain tumors, active brain metastases, spinal cord compression, or previous treatment with similar investigational drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RMC-9805 as monotherapy or in combination with RMC-6236, including dose exploration and dose expansion
Follow-up
Participants are monitored for safety, tolerability, and clinical activity after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RMC-9805
Find a Clinic Near You
Who Is Running the Clinical Trial?
Revolution Medicines, Inc.
Lead Sponsor